Celldex Therapeutics, Inc. (NASDAQ:CLDX) Holdings Lifted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 128.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 15,421 shares of the biopharmaceutical company’s stock after purchasing an additional 8,683 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Celldex Therapeutics were worth $390,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Point72 DIFC Ltd boosted its holdings in Celldex Therapeutics by 101.7% during the third quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 7,116 shares in the last quarter. Creative Planning acquired a new position in Celldex Therapeutics in the third quarter worth approximately $504,000. Handelsbanken Fonder AB increased its holdings in shares of Celldex Therapeutics by 52.9% in the fourth quarter. Handelsbanken Fonder AB now owns 21,100 shares of the biopharmaceutical company’s stock valued at $533,000 after buying an additional 7,300 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in shares of Celldex Therapeutics by 191.2% during the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock valued at $548,000 after acquiring an additional 10,581 shares during the last quarter.

Celldex Therapeutics Trading Down 5.9 %

Shares of Celldex Therapeutics stock opened at $19.35 on Tuesday. Celldex Therapeutics, Inc. has a 1 year low of $19.31 and a 1 year high of $53.18. The company has a market cap of $1.28 billion, a P/E ratio of -7.53 and a beta of 1.60. The stock has a 50-day moving average price of $23.75 and a 200 day moving average price of $28.80.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CLDX. The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday. Finally, UBS Group began coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price for the company. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $55.38.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.